The Molecular Glue Drug Development Summit returns to Boston with new insights and opportunities!

With powerful partnerships lighting up the industry – like Biogen & Neomorph, Inc.’s groundbreaking $1.45 billion collaboration and Novartis joining forces with Monte Rosa Therapeutics for a $150 million deal – the space of molecular glue is definitely heating up.

There’s no better time to secure your spot at the 3rd Molecular Glue Drug Development Summit in January, where top innovators will share first-hand insights into the design and optimization of molecular glues for previously unusable targets!

You can expect over 17 in-depth case studies from companies like Novartis, Pfizer, Neomorph, PhoreMost and GSK, plus over 9 hours of interactive networking, this year is one you don’t want to miss!

View the official brochure here:

Don’t forget that you can save up to 20% by registering with your colleagues!